Show simple item record

dc.contributor.authorOrrell, Martin
dc.date.accessioned2018-10-25T14:21:18Z
dc.date.available2018-10-25T14:21:18Z
dc.date.issued2018
dc.identifier.citationChester, H., Clarkson, P., Davies, L., Hughes, J., Islam, M. S., Kapur, N., Orrell, M., Peconi, J., Pitts, R., Poland, F., et al. (2018). Cognitive aids for people with early stage dementia versus treatment as usual (Dementia Early Stage Cognitive Aids New Trial (DESCANT)): study protocol for a randomised controlled trial. Trials, 19 (1), pp.546.en
dc.identifier.other10.1186/s13063-018-2933-8
dc.identifier.urihttp://hdl.handle.net/20.500.12904/8018
dc.description© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
dc.description.abstractBACKGROUND: There is a growing need for an evidence-based approach to home support for people with dementia and their carers following diagnosis but research on the effectiveness and cost-effectiveness of different approaches is sparse. The Dementia Early Stage Cognitive Aids New Trial (DESCANT) will evaluate the clinical and cost-effectiveness of a range of memory aids, training and support to people with mild to moderate dementia and their carers at home and compares that intervention with treatment as usual. METHODS/DESIGN: This is a multi-site, pragmatic randomised trial preceded by a feasibility study and internal pilot. We aim to allocate at random 360 pairs comprising a person with mild to moderate dementia and an identified carer between the DESCANT intervention and treatment as usual. We assess participants at baseline, 13 and 26 weeks. The primary outcome measure is the Bristol Activities of Daily Living Scale; other participant outcomes include cognition, quality of life, activities of daily living and social networking; carer outcomes include quality of life, sense of competence and mental health. To enhance this quantitative evaluation we are conducting a qualitative component and a process evaluation to assess the implementation process and identify contextual factors associated with variation. DISCUSSION: The DESCANT intervention reflects current policy to enhance the capabilities of people with dementia after diagnosis and their carers. If it is clinically and cost-effective, its modest nature and cost will enhance the likelihood of it being incorporated into mainstream practice. TRIAL REGISTRATION: Current Controlled Trials, ISRCTN12591717 . Registered on 29 July 2016. Protocol number: 31288: North West - Haydock Research Ethics Committee, 20/06/2016, ref.: 16/NW/0389.en
dc.description.urihttps://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-2933-8en
dc.formatFull text uploaded
dc.subjectCost-benefit analysisen
dc.subjectDementiaen
dc.subjectQuality of lifeen
dc.subjectCarersen
dc.titleCognitive aids for people with early stage dementia versus treatment as usual (Dementia Early Stage Cognitive Aids New Trial (DESCANT)): study protocol for a randomised controlled trialen
dc.typeArticleen
refterms.dateFOA2021-06-14T09:30:41Z


Files in this item

Thumbnail
Name:
Chester 2018 1-11.pdf
Size:
1.539Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record